Immunic Targets Multiple Sclerosis Market with Positive Phase 3 Data and Long-Term Clinical Study Results

Immunic Inc's CEO, Dr. Daniel Vitt, highlighted the significance of the Phase 2 CALLIPER study, which demonstrated a 31% reduction in confirmed disability worsening in patients with progressive multiple sclerosis. The study also showed a 34% reduction in those without baseline gadolinium lesions, indicating a potential neuroprotective effect of vidofludimus calcium. Long-term results from the EMPhASIS study further support the drug's potential, with 92.3% of relapsing-remitting MS patients remaining free of 12-week confirmed disability worsening after 144 weeks.